Universal Ibogaine (FRA:JC4) Total Receivables: €0.39 Mil (As of Apr. 2025)


What is Universal Ibogaine Total Receivables?

Universal Ibogaine FRA:JC4 Total Receivables is €0.39 Mil as of Apr. 2025.

Universal Ibogaine's Total Receivables for the quarter that ended in Apr. 2025 was €0.39 Mil.

Universal Ibogaine Total Receivables Related Terms

Universal Ibogaine Total Receivables Historical Data

* Premium members only.

The historical data trend for Universal Ibogaine's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Universal Ibogaine Total Receivables Chart

Universal Ibogaine Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Jul22 Jul23 Jul24
Total Receivables
Get a 7-Day Free Trial 0.02 0.01 0.18 0.05 0.13

Universal Ibogaine Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.13 0.09 0.13 0.39

Universal Ibogaine Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €0.39 Mil mean?
Universal Ibogaine (FRA:JC4) has a Total Receivables of €0.39 Mil as of Apr. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Universal Ibogaine and its competitors.
Is Universal Ibogaine's Total Receivables too high?
Universal Ibogaine's current Total Receivables is €0.39 Mil.
How does Universal Ibogaine's Total Receivables compare to LABT and CALC?
Universal Ibogaine's Total Receivables of €0.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Universal Ibogaine and its competitors. Universal Ibogaine's current Total Receivables is €0.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universal Ibogaine stock overvalued right now?
Universal Ibogaine (FRA:JC4) has a current Total Receivables of €0.39 Mil. The current Total Receivables is €0.39 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Universal Ibogaine (FRA:JC4), the current Total Receivables is €0.39 Mil as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Universal Ibogaine Business Description

Address C/o Cas Corporate Governance Services Inc, 815 - 8th Avenue South west, Suite 600, Calgary, AB, CAN, T2P 3P2
Universal Ibogaine Inc is in the initial stages of implementing and financing its business plan, which is to develop a network of addiction treatment clinics and to undertake a planned clinical trial for research in Canada into the use of ibogaine, a natural plant-based substance, for addiction treatment. Its mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.